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Abstract
The purpose of this study was to investigate whether MURC/cavin-4, a plasma membrane
and Z-line associated protein exhibiting an overlapping distribution with Caveolin-3 (Cav-3)
in heart and muscle tissues, may be expressed and play a role in rhabdomyosarcoma
(RMS), an aggressive myogenic tumor affecting childhood. We found MURC/cavin-4 to be
expressed, often concurrently with Cav-3, in mouse and human RMS, as demonstrated
through in silico analysis of gene datasets and immunohistochemical analysis of tumor
samples. In vitro expression studies carried out using human cell lines and primary mouse
tumor cultures showed that expression levels of both MURC/cavin-4 and Cav-3, while being
low or undetectable during cell proliferation, became robustly increased during myogenic
differentiation, as detected via semi-quantitative RT-PCR and immunoblotting analysis. Fur-
thermore, confocal microscopy analysis performed on human RD and RH30 cell lines con-
firmed that MURC/cavin-4 mostly marks differentiated cell elements, colocalizing at the cell
surface with Cav-3 and labeling myosin heavy chain (MHC) expressing cells. Finally,
MURC/cavin-4 silencing prevented the differentiation in the RD cell line, leading to morpho-
logical cell impairment characterized by depletion of myogenin, Cav-3 and MHC protein lev-
els. Overall, our data suggest that MURC/cavin-4, especially in combination with Cav-3,
may play a consistent role in the differentiation process of RMS.
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Introduction
Rhabdomyosarcoma (RMS) is a myogenic tumor classified as the most common soft-tissue
malignancy of childhood [1–3]. Despite the expression of proteins required for myogenesis,
such as the bHLH (basic helix-loop-helix) transcription factors myogenin and MyoD (myo-
genic differentiation protein) [4–6], RMS cells fail to complete myogenic differentiation [7].
Histopathological criteria define two predominant subtypes referred to as embryonal (eRMS)
and alveolar (aRMS), accounting for about 60% and 25% of all RMS, respectively [8]. While
eRMS is composed of spindle-shaped or round cells resembling embryonic skeletal muscle,
aRMS is formed by aggregates of small round undifferentiated cells separated by dense hyali-
nized fibrous septa reminiscent of lung alveolar architecture. Patients who have localized RMS
have a 5-year survival greater than 70% following a multimodal approach that includes chemo-
therapy, radiation therapy, and surgery; yet, overall survival of patients with metastasis remains
poor [9, 10]. The genomic landscape causative of eRMS is characterized by a number of genetic
aberrations, including the loss of heterozygosity at 11p15.5 responsible of IGF-2 (insulin-like
growth factor 2) overexpression [11, 12], gain of chromosomes [13, 14], somatic mutations in
cell cycle genes (i.e., CTNNB1, FBXW7 and BCOR) [15], and in several tyrosine kinase genes
(i.e., PDGFRA, ERBB2, FGFR4) [16] and transducers (i.e., NRAS, KRAS,HRAS, PIK3CA,
CTNNB1) [17, 18] that lead to deliberate activation of tyrosin kinase receptors /RAS (rat sar-
coma viral oncogene) /PI3K (phosphoinositide 3-kinase) axis [15]. In addition, defects in the
p53 pathway [19], Sonic Hedgehog signaling [20–23] and sarcomeric proteins involved in mus-
cular contraction and integrity (i.e., dystrophin, alpha-sarcoglycan and dysferlin) have been
reported to favor eRMS formation [24–29]. Conversely, aRMS is dominated by a t(2;13)(q35;
q14) chromosomal translocation that juxtaposes the DNA binding domains of the PAX3
(paired box 3) gene in frame with the partial DNA binding domain and full transactivation
domain of the FOXO1 (forkhead box O1) gene, resulting in the expression of the fused Pax3--
Foxo1 transcription factor [30]. This factor drives transcription of numerous Pax-3 down-
stream genes in a deliberate manner, contributing to suppress apoptosis and differentiation
processes [31, 32] and conferring resistance to stress conditions such as irradiation in vitro and
in vivo [33]. To date, the presence of a PAX3–FOXO1 gene fusion is a strong indicator of poor
prognosis as fusion-negative aRMS have better resolution mimicking the clinical course of
eRMS in the majority of patients [34, 35].
Caveolins (i.e., Cav-1,-2,-3) [36, 37] and Cavins (i.e., Cavin-1,-2,-3,-4) [38–43] are family
proteins that cooperate in the biogenesis and function of caveolae, specialized invaginations of
the plasma membrane involved in a variety of cellular processes, including endocytosis, lipid
homeostasis and intracellular signalling [44, 45]. Lack or improper function in some of these
protein members have been reported to affect caveolar function, hence disturbing the whole
body homeostasis and contributing significantly in the onset and/or progression of diseases
like diabetes, muscular dystrophies and cancer [44, 45]. We [46–48] and others [49] have previ-
ously documented the expression of Caveolins in RMS and more recently shown the important
contribute of Cav-1 and Cavin-1 on tumor growth [48, 50]. In this work we have investigated
whether Muscle-Restricted Coiled-coil (MURC)/cavin-4, a plasma membrane and Z-line asso-
ciated protein exhibiting an overlapping distribution with Cav-3 in heart and muscle tissues
[51, 52], may be expressed and play a role in RMS. For this purpose, we have used an in silico
approach combined with the immunohistochemical analysis of tumor samples. In addition, we
have investigated MURC/cavin-4 expression in vitro by means of human cell lines and mouse
primary tumor cultures established from conditional transgenic mice [53, 54]. Finally, the
effects ofMURC/CAVIN-4 gene knock-down on the proliferation and differentiation of
human embryonal RD cell line have been evaluated.
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Materials and Methods
All reagents were from Sigma-Aldrich (Milan, Italy), unless otherwise stated. Cell culture materi-
als were purchased from Jet-Biofil (Carlo Erba Reagents-Dasit Group, Cornaredo, Milan, Italy).
Microarray gene expression data analysis
All analyses of microarray gene expression data were performed with the Partek Genomics
Suite software version 6.6 (Partek, St. Louis, MO, USA) and R software 3.02 (free version).
Briefly, the microarray raw dataset with the accession number GSE22520 [54], deposited in the
NCBI Gene Expression Omnibus database, were reprocessed by the background correction,
normalization and summarization of probe intensities using the robust multiarray average
analysis to determine the specific hybridizing signal for each probe set. The ILMN_1228951,
ILMN_2603299 and ILMN_1241214 probes were representative ofMURC/CAVIN-4, CAV-3
andMHC transcript, respectively. After background correction, the data expression were cor-
rected for perfect match intensity and were transformed in base-2 logarithm [55]. Quality con-
trol was performed by investigating principal component analysis to detect grouping patterns
in the samples and identify the outliers, as well as for evaluating whether batch effect signifi-
cantly affected the data. To detect if each gene was differentially expressed between mouse
aRMS/eRMS vs skeletal muscle samples, we analyzed the median differences using a Kruskal—
Wallis test. To visualize gene clustering, we employed the heat map analysis. A heat map is a
graphical representation of the data where the individual values contained in a matrix are rep-
resented with colors. The method displays the genes on the x-axis and the 21 samples on the
y-axis, adding also two dendrograms which are the output of two hierarchical cluster analyses
computed on genes and samples, respectively. In detail, rows and columns of the data matrix
are reordered based on row and column means; in this way similar values are placed near each
other according to the clustering algorithm [56]. Data are standardized then allowing compari-
sons among potentially very different scale values. p-values< 0,05 were used as criteria to eval-
uate significant difference in gene expression.
Antibodies
The following primary antibodies were used: rabbit polyclonal anti-MURC/cavin-4 for immu-
nohistochemical analysis (Code: HPA020973, Sigma-Aldrich, Milan, Italy); goat polyclonal
anti-MURC/cavin-4 for immunoblotting analysis (Code: SC-163021, Santa Cruz Biotechnol-
ogy, Dallas, TX, USA); rabbit polyclonal anti-MURC/cavin-4 for immunofluorescence analysis
(as described in [52]); mouse monoclonal anti-Cav-3 (Code: 610420, BD Transduction Labora-
tories, Buccinasco, Milan, Italy); rabbit anti-myogenin (Santa Cruz Biotechnology, Dallas, TX,
USA, 1:500 dilution); mouse monoclonal anti-MHC (Code: SC-32732, Santa Cruz Biotechnol-
ogy, Dallas, TX, USA); mouse monoclonal anti-total and—phosphorylated ERK1/2 (extracellu-
lar regulated kinase 1/2) (Tyr204) (Code: SC-135900 and SC-7383, Santa Cruz Biotechnology,
Dallas, TX, USA); mouse monoclonal anti-GAPDH (glyceraldehyde 3-phosphate dehydroge-
nase) (Code: MAB374, Millipore, Darmstadt, Germany) and mouse monoclonal anti-alpha-
tubulin (Code: T5168, Sigma-Aldrich, Milan, Italy).
Immunohistochemical analysis. Mouse tumor samples were established from transgenic
mouse models at the Oregon Health & Science University, in accordance with the Guidelines
for the Care and Use of Laboratory Animals, following approval by the Institutional Animal
Care and Use Committee (IACUC) at the University of Texas Health Science Center at San
Antonio or Oregon Health and Science University. Every effort was made to minimize suffer-
ing in tumour bearing animals, as described in [54]. Formalin-fixed paraffin embedded tissue
samples from patients who underwent surgery were retrieved from the archive of the
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Department of Pathology, Spedali Civili of Brescia, in agreement with protocols approved by the
Institutional Review Board (IRC), Spedali Civili (Brescia, Italy), and upon written informed con-
sent from the patient. Sections of 2 micron were cut from paraffin embedded blocks and sub-
jected to immunohistochemical (IHC) analysis. Briefly, sections were de-waxed, re-hydrated
and endogenous peroxidase activity blocked by 0.3% H2O2/methanol for 20 minutes. Heat-
induced antigen retrieval was performed using a microwave-oven in 1 mM Citrate buffer (pH
6.0). Sections were then washed in Tris Buffered Saline (TBS) (pH 7.4) and incubated at 37°C
overnight in TBS/1% bovine serum albumin (BSA) with the specific primary antibody. Single
immunostain has been revealed by CheMATE En Vision HRP Labelled Polymer system
(DAKO, Milan, Italy) or NovoLinkTM Polymer Detection System (NovocastraTM laboratories
Ltd, Milan, Italy) followed by diaminobenzydine as chromogen and Haematoxylin as counter-
stain. For double immunostains, after completing the first immune reaction, the second
primary antibody has been applied and labelled using MACH 4TMUniversal AP Polymer
Kit (Biocare Medical, Milan, Italy); chromogen reaction was developed with Ferangi
BlueTM Chromogen System (Biocare Medical, Milan, Italy) and nuclei were counterstained
with Methyl Green. Images have been acquired by Olympus DP70 camera mounted on Olym-
pus Bx60 microscope, using CellF imaging software (Soft Imaging System GmbH, Berlin,
Germany).
Cell cultures and drug treatments. In vitro studies were conducted using the human
embryonal RD cells, RD12, RD18 and alveolar RH30 cells, as described in [50]; the primary
mouse embryonal U57810 and alveolar U23674 cultures were derived from transgenic mice in
which either p53 loss or concomitant p53 loss and Pax3-Foxo1 knock-in was restricted to
Myf6 (myogenic factor 6)-positive myoblasts, respectively [53, 54]. Cells were routinely main-
tained under standard conditions (37°C and 5% CO2 in humidified incubator) in a growth
medium (GM), consisting of high-glucose Dulbecco’s Modified Eagle’s Medium (DMEM) sup-
plemented with 10% fetal bovine serum (FBS) and 100 μg/ml penicillin—streptomycin antibi-
otics; RH30 cells also received 1% L-Glutamine. To induce myodifferentiation, all the cell lines
reaching the confluence received a daily renewed differentiating medium (DM), consisting of
DMEM supplemented with 2% horse serum; alternatively, embryonal cells received every day
fresh DM added with the chemical PD098059 (10 μM, dissolved in dimethylsulfoxide vehicle,
DMSO), a synthetic upstream inhibitor of the RAS/ERK cascade that enhances differentiation
[57].
Generation of MURC/cavin-4 silenced clones
We stably transfected human RD cells with either four different GFP-tagged short hairpin
RNAs tailored toMURC/CAVIN-4 sequence (shMURC) or one random OFF-target sequence
as a negative control (shOFF), using Transit-LT1 reagent (Tema-Ricerca, Castenaso, Milan,
Italy) according to the manufacturer's protocol. The following shRNA sequences cloned
in pGFP-V-RS constructs (Tema-Ricerca/ORIGENE, Castenaso, Milan, Italy) were used
(superscript numbers indicate the recognized nucleotides over the MURC sequence):
shMURC 103–131 (clone TG315318A—GI361266, 50-TCCACCAGAATCGCCTGTCGAGTGT
TACA-30); shMURC 901–929 (clone TG315318B—GI361267, 50-ACCGAACAGTGGCT
GAAGGTGAG GAATGT-30); shMURC 178–206 (clone TG315318C—GI361268, 50-ACAAAG
TAGCCTC CATCGTGGACAGTGTG-30); shMURC 366–394 (clone TG315318C—GI361269,
50-TATTC CAGGAGAAGTTTCGGTGTCCGACA-30); shOFF (clone TR30013, 50-CTTCAA
GACCACATA CAGATCCAAGAAAC-30). After antibiotic selection, the GFP staining labeled
near the totality of cells and the experiments raised similar results in all the selected clones.
MURC/cavin-4 Expression in Rhabdomyosarcoma
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Giemsa and crystal violet staining
We stained the cells with Giemsa reactive to visualize the presence of elongated myotube-like
structures that are indicative of myogenic differentiation. To this end, cells were washed in phos-
phate buffered saline (PBS) and fixed in methanol at -20°C. Cells were given Giemsa reactive for
4 hours, then were washed three times in PBS. We employed the crystal violet assay to measure
cell proliferation. To this end, cells were seeded in 24-well plates at a density of 10x103 and fixed
in PFA after 24, 48 and 72 hours in GM. Cells were stained for 10 min with crystal violet solution
(0.2% in PBS with 20% methanol) and then collected in 600 μl of SDS solution (1% in PBS).
Absorbance of the samples was measured by reading the plate at 540 nm emission wavelengths
and was proportional to the amount of proliferating cells that incorporated the crystal violet.
RNA isolation and semi-quantitative RT-PCR analysis
Total RNA was isolated using a Tri-reagent kit and treated with DNA-free DNase (Promega,
Madison, WI, USA). RNA (2 μg) was reverse-transcribed in the presence of 400 Units of Molo-
ney murine leukemia virus reverse transcriptase (MMLV-RT) enzyme (Promega, Madison,
WI, USA) and the obtained cDNA template was used for PCR analysis using specific
forward and reverse primers (250 nM). In particular, a 560 bp-long humanMURC/
CAVIN-4 fragment was amplified with 50-ATGAAGACCAAGACGCTGC-30 and
50-ATGTGCTCCTTGCCTGACTT-30 primers, a 558 bp-long mouseMURC/CAVIN-4
fragment with 50- AATGCTGATAAAATCCACCAGAA-30 and 50-ATGTGCTCCTTGCCT
GACTT-30 primers and a 267 bp-long GAPDH fragment (complementary to both human and
mouse forms) with 50-CGTGGAGTCTACTGGCGTCTTC-30 and 50-GGGAGTTGTCATATTT
CTCGTGGTT-30 primers.
Immunoblotting analysis. Protein concentration was calculated by Bradford reagent
assay. Equal amounts of protein samples were separated by SDS-PAGE under reducing condi-
tions and transferred to polyvinylidine fluoride (PVDF) membranes. Incubation with specific
primary antibodies was followed by horseradish peroxidase-conjugated secondary antibodies
(1:4,000 dilution), including donkey anti-goat (Santa Cruz Biotecnology, Dallas, TX, USA),
goat anti-mouse IgG (Santa Cruz Biotechnology, Dallas, TX, USA) and donkey anti-rabbit IgG
(Thermo Scientific-Pierce, Erembodegem, Belgium). The resulting immunocomplexes were
visualized using enhanced chemiluminescence reagent (GeneSpin, Milan, Italy). Immunoreac-
tive bands were quantified using densitometric analyses (Software Gel Pro Analyzer, version 4,
MediaCybernetics Inc, Rockville, MD, USA). For detection of MURC/cavin-4, myogenin,
MHC, tubulin and ERK1/2 (total and-phosphorylated on Tyr204), protein homogenates were
prepared by harvesting cells in cold RIPA lysis buffer, composed by 20 mM Tris-HCl (pH 7.6),
1% Nonidet P40, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM NaCl, and a cocktail of prote-
ase inhibitors (Roche, Monza, Monza Brianza, Italy) plus phosphatase inhibitors (1 mM
Na3VO4 and 4 mMNaF). Total homogenates were then centrifuged at 12,000 x g for 10 min-
utes at 4°C. Triton-insoluble membranous fractions were used for detection of Cav-3 and were
obtained by harvesting the cells in cold Triton buffer, composed by 10 mM Tris-HCl (pH 8.0),
1% Triton X-100, 5 mM EDTA, 150 mMNaCl, and a cocktail of protease inhibitors plus phos-
phatase inhibitors, followed by centrifugation (15,000 x g for 15 minutes at 4°C). Soluble- and
detergent-insoluble fractions were obtained by ultra-centrifugation (100,000 x g for 1 hour at
4°C) of total lysates obtained from cells harvested in cold Triton buffer.
Immunofluorescence analysis
Cells were cultured onto 12 mm glass coverslips coated with FBS and fixed with paraformalde-
hyde (PFA) for 15 minutes at room temperature (RT); PFA-fixed cells were then permeabilized
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in 0.1% saponin in PBS for 10 minutes before subsequent incubation in 50 mMNH4Cl in PBS
for 10 minutes and in blocking solution (composed of 0.2% BSA and 0.2% fish skin gelatin in
PBS) for 20 minutes at RT. A 30-minutes incubation in blocking solution containing primary
antibodies was followed by 4×5 minutes PBS washes before incubation in blocking solution
containing fluorescently tagged secondary antibodies for 20 minutes. After further 4×5 minutes
PBS washes, the cells were incubated with DAPI for 1 minute just before rinsing in water and
then mounted in Mowiol. Image acquisition of cells, indirectly labeled with Alexa fluorophores
(Invitrogen, Life Technologies, Monza, Monza Brianza, Italy), was performed at RT in Acqua-
Poly Mount medium (Polysciences, Warrington, PA, USA) using a confocal microscope with
photomultiplier tube detectors (LSM 510 Meta; Carl Zeiss, Oberkochen, Germany) equipped
with a 63x oil immersion objective (Carl Zeiss Inc., Oberkochen, Germany). The data were cap-
tured using the LSM 510 Meta software (Carl Zeiss, Oberkochen, Germany) and unprocessed
images were assembled using Photoshop (CS3; Adobe).
Statistical analysis
The differences between the groups were analyzed by unpaired Student's t tests and One-Way
ANOVA test (with Dunnet's post-test), using Prism 4 software for Windows (GraphPad Soft-
ware, San Diego, CA, USA). Statements of significance were based on a p-value of less than 0.05.
Results
In silico analysis predicts correlation between MURC/cavin-4 and Cav-3
in RMS tumors
To analyze the transcriptional levels ofMURC/CAVIN-4, CAV-3 andMHC in RMS, we
employed an in silico approach using microarray data available in the NCBI Gene Expression
Omnibus database with the accession number GSE22520, which were previously generated by
the analysis of primary tumors established frommouse models [54]. By evaluating the variability
in the expression levels ofMURC/CAVIN-4, CAV-3 andMHC, as detected in aRMS (n = 11) and
eRMS (n = 7) tumors and skeletal muscle samples (n = 3) (Fig 1A), we found that the medians of
CAV-3 andMHC in three groups were statistically different with a p-value of 0.0398 and 0.0222,
respectively, while the levels ofMURC/CAVIN-4 in tumor samples did not significantly differ
from those observed in skeletal muscle (p-value = 0.1013) (Fig 1B). Furthermore, we evaluated
by means of the Pearson correlation coefficient (ρ) thatMURC/CAVIN-4 and CAV-3 have a
high positive linear relationship (ρ = 0.7123) that is statistical significant (p-value = 0.0003)
(Fig 1C), meaning that CAV-3 andMURC/CAVIN-4 concurrently increased or decreased in the
samples analyzed. To better visualize the gene expression levels we then employed the heat map
method (Fig 1D). Consistent with the correlation coefficient, heat map representation confirmed
thatMURC/CAVIN-4 and CAV-3 genes were clustered together, showing a similar expression in
aRMS, eRMS and skeletal muscle samples; on the other hand,MHC had an independent behav-
ior, reaching higher values in correspondence to skeletal muscle samples, while being at lower
values in tumor samples. Interestingly, using data source relative to analysis of 139 primary
human tumors [58] (available at the Oncogenomics databases: https://pob.abcc.ncifcrf.gov/cgi-
bin/JK), we found that CAV-3 expression levels correlated with higher probability of patient’s
survival, as obtained by means of the Kaplan-Meier survival estimation (Fig 1E); In particular,
the three-year overall survival estimated in tumors with high vs low CAV-3 expression was about
85% and 60%, respectively (Fig 1E), suggesting that tumors with higher CAV-3may have a more
positive prognosis. Unfortunately, it was not possible to perform the same analysis forMURC/
CAVIN-4 because the probe was absent in the microarray.
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MURC/cavin-4 expression frequently matches that of Cav-3 in RMS
tumors
We performed an immunohistochemical (IHC) analysis using a total of 17 samples amongst
mouse and human tumors (Table 1). Prior to staining tumors, we tested the specificity of
MURC/cavin-4 antibody on mouse tissues, including heart, skeletal muscle and spleen; the
Fig 1. In silico analysis. A) Dot-plots and bar charts representative of the transcript levels ofMURC/CAVIN-4, CAV-3 andMHC genes in aRMS (n = 11) and
eRMS (n = 7) vs skeletal muscle (n = 3) samples, as calculated after in silico analysis of microarray data. In the plot, each dot is a sample of the original data.
The Y-axis represents the log2 normalized intensity of the gene and the X-axis represents the different types of samples. Bars represent the
average ± standard error of the mean. B)MURC/CAVIN-4, CAV-3 andMHC transcript levels were represented with box-plots.MURC/CAVIN-4 gene was not
differentially expressed between mouse aRMS and eRMS in comparison to skeletal muscle samples, as determined by Kruskal-Wallis test. p-values < 0,05
were used as criteria to evaluate significant difference in gene expression. In each box-plot the median value (black line in the box) is reported in
correspondence of every subgroups. C) Heat map analysis onMURC/CAVIN-4, CAV-3 andMHC transcript levels in aRMS, eRMS and skeletal muscle
samples. Low values of the gene expression are represented with blue, mean values are represented with yellow while high values are represented in red. D)
Kaplan-Meier analysis was performed using microarray data from 139 primary human samples [54]. The overall survival in RMS patients with respect to Cav-
3 expression is indicated with red and blue curve, respectively.
doi:10.1371/journal.pone.0130287.g001
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results showed that MURC/cavin-4 staining was specifically restricted to heart and skeletal
muscle (Fig 2A), and similar results were obtained on human tissues (not shown). In tumors,
MURC/cavin-4 stained near the totality of samples with a proportion of cells ranging from 5%
up to 90% (Table 1), as shown in representative pictures (Fig 2B). Since the observed co-expres-
sion of MURC/cavin-4 and Cav-3 in skeletal muscle [52], we investigated whether this may
occur also in RMS. For this purpose, IHC analysis carried out on serial tumor sections showed
that MURC/cavin-4 staining consistently overlaps that of Cav-3 in a significant number of
foci/cells (Fig 3A). These findings were then confirmed by double IHC analysis carried out on
human samples, where near the totality of MURC/cavin-4 expressing cells were also positive to
Cav-3 (Fig 3B). Of note, we also observed a few number of Cav-3 expressing cells that were
negative to MURC/cavin-4 (Fig 3B), although the majority of the cells were doubly stained for
both MURC/cavin-4 and Cav-3.
Expression of Cav-3 or MURC/cavin-4 was semi-quantitatively scored on the basis of per-
centage of positive immunoreactive cells and staining intensity, the latter evaluated as follows:
Table 1. IHC evaluation of MURC/cavin-4 and Cav-3 expression levels in RMS tumors.
Mouse tumor specimens
Sample
name
Histotype Site of
Onset
Morphology Genetic background MURC/cavin-4 Cav-3
% of positive
cells
Intensity
(0-1-2-3)
% of positive
cells
Intensity
(0-1-2-3)
U86 eRMS buttock Spindle cell Myf5Cre-PTC1+/-; p53-/- 15% 1 20% 1
U216 eRMS back Spindle cell Pax7CreER-PTC1+/-;
p53-/-
5% 1 10% 1
U35 eRMS right-arm Spindle cell Myf5Cre-PTC1+/-; p53-/- 90% 2 90% 2
U222 aRMS Arm Epitheliod Myf6Cre-Pax3P3F/P3F;
p53-/-
40% 2 5% 1
U87 aRMS Arm Epitheliod Myf6Cre-Pax3P3F/P3F;
p53-/-
40% 1 40% 1
U11 aRMS left-leg Round cell
neoplasm
Myf5Cre-Pax3P3F/P3F;
p53-/-
40% 2 with rare
elements 3
50% 2
U89 aRMS Leg Solid variant,
epitheliod
Mcre-Pax3P3F/P3F; p53-/- 30% 2 20% 2
Human tumor specimens
Case
number
Histotype Site of
Onset
Genetic background MURC/cavin-4 Cav-3
% of positive
cells
Intensity
(0-1-2-3)
% of positive
cells
Intensity
(0-1-2-3)
1 eRMS Occipital Unknown 40% 2 50% 3
2 eRMS Nasopharinx Unknown 5% 1 10% 1
3 eRMS Thigh Unknown 40% 2 60% 3
4 eRMS Nasopharinx Unknown 60% 2 with rare
elements 3
70% 3
5 eRMS Pelvic Unknown 80% 2 with rare
elements 3
90% 3
6 eRMS Arm Unknown 80% 3 90% 3
7 aRMS Perineum Unknown 20% 3 90% 3
8 aRMS Thigh Unknown 10% 2 70% 2
9 aRMS Calf Unknown 30% 2 with rare
elements 3
80% 2
10 aRMS Elbow Unknown 80% 2 100% 3
Tumor samples employed for the immunohistochemical evaluation of MURC/cavin-4 and Cav-3.
doi:10.1371/journal.pone.0130287.t001
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1, low; 2, moderate; 3, strong staining intensity. Mouse tumors were established from trans-
genic mice with specific genetic backgrounds [54].
In vitro differentiation of human and mouse RMS cultures yields a rise in
the protein levels of both MURC/cavin-4 and Cav-3
An in vitro investigation was carried out using human cell lines (embryonal RD, RD12 and
RD18 or alveolar RH30) and mouse primary tumor cultures (embryonal U57810 and alveolar
U23674). As detected via semi-quantitative RT-PCR analysis, the transcriptionalMURC/
Fig 2. Expression of MURC/cavin-4 in RMS tumors. A) The specificity of MURC/cavin-4 antibody was tested by IHC analysis using mouse tissue samples
derived from heart, skeletal muscle and spleen. The latter was expectedly negative to MURC/cavin-4 staining (brown). Images were taken at 20x and 60x
magnification. Scale bars:100 μm. B) MURC/cavin-4 staining (brown) was evaluated by IHC analysis on mouse and human tumors (as reported in Table 1).
Skeletal muscle served as a positive control. Representative pictures were taken at 20x and 60x magnification. Scale bars:100 μm.
doi:10.1371/journal.pone.0130287.g002
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CAVIN-4 levels were consistently increased in all the cell lines cultured in differentiating
medium (DM) as compared to growth medium (GM) (Fig 4A). This evidence was confirmed
by immunoblotting analysis showing that the MURC/cavin-4 protein levels were low or almost
undetectable in all the proliferating cell lines but incremented concurrently with Cav-3 and
Fig 3. Concurrent expression of MURC/cavin-4 and Cav-3 in RMS tumors. A) Single staining (brown) of
either MURC/cavin-4 or Cav-3 was evaluated by IHC analysis on serial tumor sections established from
mouse and human tumor samples (as reported in Table 1). Representative pictures were taken at 20x and
60x magnification. Scale bars:100 μm. B) MURC/cavin-4 (brown) and Cav-3 (blue) staining was evaluated by
double IHC analysis on human tumors. Representative pictures were taken at 20x magnification, whereas
60x magnification corresponds to inset; scale bars: 100 μm. * corresponds to MURC/cavin-4 brown staining,
arrowhead corresponds to Cav-3 blue staining and arrow corresponds to double staining.
doi:10.1371/journal.pone.0130287.g003
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Fig 4. In vitro expression of MURC/cavin-4 and Cav-3 in RMS cultures. In vitro analysis of MURC/cavin-4
expression was conducted using human cell lines (embryonal RD, RD12, RD18 and alveolar RH30) and
primary mouse tumor cultures (embryonal U57810 and alveolar U23674); the mouse skeletal C2C12
myoblasts served as positive control. Cells were seeded in 60-mm dishes (at a density of 12 x 104) and
cultured in GM until confluence, followed by incubation in DM. After 72 hours in GM or DM, cells were
harvested and analyzed for transcript and protein content. A) Semi-quantitative PCR analysis was carried out
to analyze the transcriptional levels ofMURC/CAVIN-4 in the different cell lines. Mean ± SD of the relative
MURC/cavin-4 levels were normalized withGAPDH expression; **, P < 0.001; ***, P < 0.0001. Results are
representative of three independent experiments. B) Under the same conditions, immunoblotting was
performed to analyze the protein content of MURC/cavin-4, Cav-3, myogenin and MHC. Results are
representative of three independent experiments. C) The embryonal human RD and mouse U57810 cells
were seeded in 60-mm dishes (at a density of 12 x 104) and maintained in GM for up to 72 hours. Cells were
then differentiated in the presence of DM or DM added with 10 μMPD098059 for additional 72 hours. The
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myogenin during myogenic differentiation (Fig 4B); in addition, increased levels of MHC, a
marker of terminal differentiation, were only observed in eRMS lines, being aRMS lines usually
more refractory to complete the differentiation process [53, 54] (Fig 4B). Of note, in human
and mouse lines we estimated the molecular weight of MURC/cavin-4 to be approximately 50
and 42 kDa, respectively (Fig 3B). To further strengthen our findings, we also forced the differ-
entiation by co-treating the human RD and mouse U57810 cells with DM and an upstream
inhibitor of the ERK1/2 phosphorylation, namely PD098059 [57, 59]. This treatment was
indeed effective to reduce the levels of phosphorylated ERK1/2 levels in comparison to DM
and GM conditions, leading to improved morphological cell differentiation (not shown),
which was characterized by a robust increase of MURC/cavin-4, Cav-3 and MHC protein lev-
els, as detected by immunoblotting (Fig 4C). Consistent with this, the same treatment per-
formed on aRMS lines, having no effect on the extent of myogenic differentiation, did not
change the protein levels of MURC/cavin-4 and Cav-3 (not shown).
Taken together, the in vitro data suggest that MURC/cavin-4 and Cav-3 protein levels con-
currently increase during differentiation of RMS cells.
During myogenic differentiation MURC/cavin-4 and Cav-3 colocalize at
the plasma membrane in human RD and RH30 cells
We investigated the cellular distribution of MURC/cavin-4, Cav-3 and MHC using the human
embryonal RD and alveolar RH30 lines. By means of cell fractionation followed by immuno-
blotting, we observed MURC/cavin-4 protein levels to be concurrently increased with Cav-3
during cell differentiation and mainly enriched in the detergent-insoluble cell fractions (Fig
5A). In differentiated cell lines Cav-3 was found to be enriched in both cell fractions (Fig 5A),
whereas MHC was mostly detected in detergent-soluble fractions only in differentiated RD
cells (Fig 5A). Immunofluorescence analysis showed that MURC/cavin-4 staining co-localized
with that of Cav-3 at the cell surface in differentiated RD and RH30 lines, while their labelling
being hardly detectable in proliferation (Fig 5B, top panels). We also observed a strong co-
staining of MURC/cavin-4 and MHC in differentiated RD cells (Fig 5B, bottom panels), while
a weaker co-staining was visualized in a few number of likely more differentiated RH30 cells
(Fig 5B, bottom panel), despite the lack of MHC detection by immunoblotting (Fig 5A). Over-
all, these data indicate that MURC/cavin-4 and Cav-3 co-localize at the plasma membrane in
more differentiated RD cells (positive to MHC) as well as in less differentiated RH30 cells (neg-
ative to MHC).
MURC/cavin-4 silencing impairs differentiation of the embryonal RD cell
line
We investigated whether silencing MURC/cavin-4 by shRNAi may affect the myogenic differ-
entiation. For this purpose, the RD cells were transfected either with four different shMURC
vectors (shMURC 103–131; 901–929; 178–206; 366–394) or with a mixture of all (shMURC MIX), using
a random OFF-target sequence as a negative control (shOFF). To assess the levels of MURC/
cavin-4 knock-down in stably transfected clones, immunoblotting analysis was performed
loading double the amount of protein samples (160 μg) and using heavy exposures, since the
low MURC/cavin-4 expression detected during cell proliferation. The analysis on five
derived cell homogenates were then used to analyze the protein content of MURC/cavin-4, Cav-3, MHC,
ERK1/2 (both phosphorylated and total forms) by immunoblotting. Protein bands were quantified by
densitometry after normalization with respect to tubulin (n = 3). **, P < 0.001.
doi:10.1371/journal.pone.0130287.g004
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Fig 5. Subcellular localization of MURC/cavin-4 and Cav-3 in the human RD and RH30 lines. A) Embryonal RD and alveolar RH30 cells were seeded in
60-mm dishes (at a density of 12 x 104) and cultured in GM for 72 hours until reaching confluence; cells were then treated with DM for additional 72 hours.
Protein homogenates were subjected to cell fractionation, and the detergent-soluble and-insoluble fractions were analysed by immunoblotting to evaluate the
protein levels of MURC/cavin-4, Cav-3, MHC and GAPDH. Results are representative of three independent experiments. B) Confocal microscopy analysis
was employed to analyze the distribution of MURC/cavin-4 (red), Cav-3 (green) and MHC (green) in RD and RH30 cells cultured in GM or DM. Nuclei were
counterstained with DAPI (blue). Samples were analyzed using a Zeiss LSM510METAmicroscope equipped with a 63x oil immersion objective. Merged
images, captured using the LSM 510 Meta software, showed an extensive co-localization of MURC/cavin-4 with Cav-3 at the cell surface as well as with
MHC in the cytosol (yellow signal). Pictures were taken at 63x magnification.
doi:10.1371/journal.pone.0130287.g005
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independent clones showed a significant down-regulation of MURC/cavin-4 levels in shMURC
MIX and shMURC 901–929 clones as compared to control shOFF cells (Fig 6A). Similar results
were also obtained by analysis ofMURC/CAVIN-4 transcript levels (not shown). We then
decided to evaluate whether MURC/cavin-4 knockdown may affect the cell cycle. As measured
by means of crystal violet assay, we found that proliferation of shMURC MIX and shMURC 901–
929 cells was similar to that of control shOFF cells over a time-course of 72 hours (Fig 6B).
The effects of MURC/cavin-4 silencing on differentiation were then evaluated by staining
cells with Giemsa reactive. While culturing the clones in the presence of DM or DM added
with 10 μM PD09859 for up to 72 hours lead shOFF cells to acquire an elongated morphology
that is characteristic of differentiation, shMURC MIX cells maintained a round-shape morphol-
ogy (similar results were observed in shMURC 901–929 cells, not shown) (Fig 6C). Under these
conditions, immunoblotting analysis showed that the increased and concurrent expression of
MURC/cavin-4, Cav-3, myogenin and MHC, as observed in shOFF cells, was severely abro-
gated in both shMURC clones (Fig 6D). In addition, immunofluorescence analysis showed that
the co-staining of MURC/cavin-4 with Cav-3 or MHC, as observed in differentiated shOFF
cells, was almost completely depleted in shMURC MIX cells (Fig 6E), and similar results were
observed in shMURC 901–929 cells (not shown).
Discussion
MURC/cavin-4 and Cav-3 are protein members of the Cavin [38–43] and Caveolin [36, 37]
families, essential coat components and regulators of caveola biogenesis [44, 45]. Both these
proteins share a restricted tissue-specific expression in cardiac and skeletal muscle tissues,
where they play different non redundant but sometimes overlapping roles. In striated muscle
MURC/cavin-4 was found to be associated to the Z-line [51], the structural border of the sarco-
mere which also serves as a platform for a large number of the Z-disc-associated proteins that
shuttle between the Z-disc and other subcellular locations to transmit signals [60].MURC/
CAVIN-4 gene knock-down or over-expression has been shown to impair or improve the dif-
ferentiation of mouse C2C12 myoblasts through decreased or increased ERK1/2 activation in
the later stages of differentiation [51]. Cav-3 is a membrane scaffolding protein [61–63] that
interacting at the sarcolemma with a number of signalling proteins, such as nitric oxide
synthase [64, 65], TGF-β (transforming growth factor-beta) receptors [66, 67] and dysferlin
[68, 69], is involved in the regulation of many processes, including skeletal muscle differentia-
tion and regeneration. Mutated Cav-3 forms affect the survival and differentiation of myoblasts
[70, 71] and are involved in the onset of cardiac and neuromuscular disorders [72–75], such as
the Limb Girdle Muscular Dystrophy 1-C [64, 65, 76, 77]. Furthermore, Cav-3 deficient mus-
cles from dystrophic patients display a loss of MURC/cavin-4 [52], suggesting that MURC/
cavin-4 and Cav-3 may together cooperate for proper functioning of skeletal muscle tissue.
RMS are pediatric tumors mainly deriving from myogenic lineages [53, 54, 78–80] and
showing distinctive traits found in skeletal muscle, including the appearance in the cytoplasm
of the typical striated bands corresponding to sarcomere structures and expression of muscle-
specific markers, such as MyoD, myogenin, muscle specific actin (MSA), desmin, sarcomeric
alpha-actin, and myoglobin. RMS cells carry genetic alterations that hinder the cell cycle with-
drawal and/or prevent the myogenic differentiation process [7]. Poorly differentiated RMS
cells have higher probability to metastasize [81], and therefore increasing their differentiation
potential could, in principle, irreversibly arrest cell proliferation to control the disease with less
side effects than conventional therapies [82]. In this context, the translational research of mark-
ers helping to predict the status of RMS cell differentiation is precious.
MURC/cavin-4 Expression in Rhabdomyosarcoma
PLOSONE | DOI:10.1371/journal.pone.0130287 June 18, 2015 14 / 21
Fig 6. Effects of MURC/cavin-4 knockdown in the RD cell line. Stably transfected RD clones (i.e., control
shOFF and five different knock-down clones, namely shMURC MIX; 103–131; 901–929; 178–206; 366–394) were
seeded in 60-mm dishes (at a density of 12 x 104) and harvested after 72 hours in GM. SDS-PAGE was
carried out loading gel with 160 μg proteins per each sample and immunoblotting was performed to evaluate
the protein levels of MURC/cavin-4. Results are representative of three independent experiments. Protein
bands were quantified by densitometry after normalization with respect to tubulin (n = 3). **, P < 0.001. B)
Crystal violet assay was employed to compare the proliferation over a time-course of 24-48-72 hours in
knock-down MURC/cavin-4 clones (i.e., shMURC MIX and shMURC 901–929) and control shOFF clone.
Results are representative of three independent experiments. C) Control shOFF and knock-down shMURC
MIX cells were seeded in 60-mm dishes (at a density of 12 x 104) and, once reached the confluence, were
differentiated in the presence of DM or DM added with 10 μMPD09859 for 72 hours. Giemsa staining was
then employed to visualize the morphological differentiation. Pictures were taken under a phase contrast
microscope at 40x magnification. Images are representative of three independent experiments. D) Under the
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In 2005, a study reported Cav-3 to be expressed in the more differentiated eRMS and aRMS
subsets, thereby configuring this protein as a useful marker to assess the degree of differentia-
tion or detect residual tumor cells that may undergo differentiation following chemotherapy
[49]. Afterwards, a study from our group has corroborated these findings showing that Cav-3
expressing cells are often positive for MHC, a marker of terminal differentiation, and further
suggesting that Cav-1, which is a marker of muscle satellite cells highly homolog to Cav-3,
instead configures as a marker of poor differentiation in RMS [46]. In the present study we
showed MURC/cavin-4 and Cav-3 to be frequently co-expressed in human RMS specimens as
well as in mouse tumors established in transgenic mouse models that authentically recapitulate
the onset and progression of eRMS and aRMS subsets [54]. Our in silico analysis revealed that
MURC/cavin-4, Cav-3 and MHC had all a similar trend of expression, being less to more
expressed in aRMS, eRMS and skeletal muscle, respectively. In addition, we found a significant
correlation between MURC/cavin-4 and Cav-3 among tumor samples and also detected an
increased survival’s probability for RMS patients with higher Cav-3 expression, indicating that
Cav-3 signature may be associated to a better prognosis, likely due a major degree of tumor dif-
ferentiation. In light of this evidence, we may hypothesize that MURC/cavin-4 may have a sim-
ilar behavior, although this still awaits further investigation. The observed in silico correlation
between MURC/cavin-4 and Cav-3 was found to occur also in vivo and in vitro; indeed, immu-
nohistochemical analysis of tumor samples detected MURC/cavin-4 staining frequently in
Cav-3 expressing cells, whereas a robust and concurrent expression of both MURC/cavin-4
and Cav-3 was observed in human RMS lines and mouse primary tumor cultures only during
differentiation. Interestingly, whereas near all the MURC/cavin-4 expressing RMS cells were
positive to Cav-3, we also recognized a number of cells positive for Cav-3 and negative for
MURC/cavin-4. This could indicate that Cav-3 expression during the differentiation process
may occur prior to MURC/cavin-4 expression. In this regard, we must also carefully taken into
account that both eRMS and aRMS tumors can frequently express myogenic markers of every
cell stage irrespective of a real differentiation program [54]. Although MURC/cavin-4 and
Cav-3 levels increased upon differentiation stimuli, this up-regulation was strongly associated
with terminal differentiation due to MHC expression only in cell lines representative of eRMS,
which are known to exhibit the greatest extent of myodifferentiation [54]. Instead, in the less
prone differentiating and more aggressive aRMS tumors [54] we noted an increased expression
of MURC/cavin-4 and Cav-3 but lack or very low expression of MHC; this means that MURC/
cavin-4 and Cav-3 co-expression cannot be univocally interpreted as readout of terminal differ-
entiation, as they may even feature an early/intermediate stage of differentiation. Likely,
MURC/cavin-4 or Cav-3 expression alone is not sufficient to efficiently predict the status of
myogenic differentiation in RMS cells. MURC/cavin-4 resemble myogenin: RMS are highly
positive for this marker, that normally increases during myogenesis, when they are enforced to
differentiate. However, myogenin itself is not predictive of the status of RMS differentiation.
In differentiating RMS cells we observed both proteins residing in the cytosol but mainly
co-localizing at the plasma membrane, indicating that their activity may underlie the proper
extent of differentiation in RMS, as occurring in skeletal muscle [51, 52]. Consistent with this,
same conditions, immunoblotting was performed to evaluate the protein content of MURC/cavin-4, Cav-3,
myogenin and MHC. Results are representative of three independent experiments. E) Confocal microscopy
analysis was employed to analyse the distribution of MURC/cavin-4 (red), Cav-3 (green) and MHC (green) in
knock-down shMURC MIX clone as compared to control shOFF clone cultured in DM. Nuclei were
counterstained with DAPI (blue). Samples were analyzed using a Zeiss LSM510 METAmicroscope and
pictures were taken with a 63x oil immersion objective.
doi:10.1371/journal.pone.0130287.g006
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MURC/CAVIN-4 gene silencing was sufficient to impair the differentiation process in the
human RD cell line, leading to loss of expression of myogenin, Cav-3 and MHC. These findings
strengthen the importance of MURC/cavin-4 as a readout of differentiation in RMS, and fur-
ther opens new interesting questions on the MURC/cavin-4-dependent mechanisms underly-
ing RMS differentiation, which will be the matter of future investigation. In this regard,
MURC/cavin-4 was shown to influence differentiation in skeletal muscle cells by ERK pathway
activation [51], whereas to modulate cardiac function by activating the Rho—ROCK (RAS
homolog/Rho-associated protein kinase) pathway and recruiting ERK to caveolae in response
to adrenergic stimulation [83][84]. In conclusion, this work points out that MURC/cavin-4,
likely cooperating with Cav-3, is required for RMS cells to undergo myogenic differentiation.
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